| Literature DB >> 10602709 |
C Z Ding1, R Batorsky, R Bhide, H J Chao, Y Cho, S Chong, J Gullo-Brown, P Guo, S H Kim, F Lee, K Leftheris, A Miller, T Mitt, M Patel, B A Penhallow, C Ricca, W C Rose, R Schmidt, W A Slusarchyk, G Vite, N Yan, V Manne, J T Hunt.
Abstract
2,3,4,5-Tetrahydro-1-(imidazol-4-ylalkyl)-1,4-benzodiazepines were found to be potent inhibitors of farnesyltransferase (FT). A hydrophobic substituent at the 4-position of the benzodiazepine, linked via a hydrogen bond acceptor, was important to enzyme inhibitory activity. An aryl ring at position 7 or a hydrophobic group linked to the 8-position through an amide, carbamate, or urea linkage was also important for potent inhibition. 2,3,4, 5-Tetrahydro-1-(1H-imidazol-4-ylmethyl)-7-(4-pyridinyl)-4-[2-(t rifluo romethoxy)benzoyl]-1H-1,4-benzodiazepine (36), with an FT IC(50) value of 24 nM, produced 85% phenotypic reversion of Ras transformed NIH 3T3 cells at 1.25 microM and had an EC(50) of 160 nM for inhibition of anchorage-independent growth in soft agar of H-Ras transformed Rat-1 cells. Selected analogues demonstrated ip antitumor activity against an ip Rat-1 tumor in mice.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10602709 DOI: 10.1021/jm990391w
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446